Recent

% | $
Quotes you view appear here for quick access.

iPath S&P 500 VIX ST Futures ETN Message Board

rpbossman 8 posts  |  Last Activity: Mar 17, 2015 11:11 PM Member since: Aug 26, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • You know all about that right. I can't believe people are selling. We miss by a fraction but every thing else shows huge improvement over current therapies'. Liver and Brain cancer 10.4 over 4.4 moths survival rate.
    To me this is big. Initial reaction is to go down but I think we end up tomorrow. Maybe $15 or higher. Once everyone figures out the FDA will make 102 available immediately. By the way 102 had No Kennedy Grade four diarrhea. You know a real gusher of #$%$.

  • Someone I know is on Vascepa and experience great results. I just talked with this person last night and they told me the price was going up which caught them off guard. Introductory pricing is getting us the scripts, then when the results are great the price then goes up. He said he is trying to get a better price then what they want to charge him. To me this is a good sign for AMRN. While AMRN may not get full price yet on the product it can certainly up the price somewhat in a sort of negotiating type arena. The word is getting out on how well Vascepa works so higher and higher script counts are on the way along with a stronger pricing model..

  • 102 has not failed yet. The blind study has not be revealed to anyone. So this is all conjecture on the part of the naysayers.

  • Financials will look good, much better year over year. Also big Hint as what is to come. NKTR expands office space. You don't go out and lock in new office space unless it warrants.

  • one of my local community board members the other day. He was telling me about his health and heart attacks over theyears. Tells me he is on some kind of new fish oil. It was Vascepa. Said whenever he picks up prescription it takes a few days as the CVS doesn't usually carry it. It needs to be shipped in. The fact he's using it, and we're in CAlifornia, must mean things are starting to expand for the product.

  • They can only walk it down so far before shorts have to cover. Almost 25% off the top, now is the time to buy.

  • Nektar grabs more Mission Bay space on cusp of growth spurt

    Jan 20, 2015, 5:44am PST Updated: Jan 20, 2015, 11:08am PST

    Howard Robin is president and CEO of Nektar Therapeutics. Nektar Therapeutics Inc. is grabbing space in San Francisco's Mission Bay and could hire more people.

    Nektar Therapeutics Inc. is growing up, so it's taking another 20,000 square feet in San Francisco's Mission Bay and could hire another 150 people.

    The new space — the entire second floor of a structure connected to Nektar's headquarters and R&D center at 455 Mission Bay Blvd. South — is expected to fill quickly after the company moves in June or July.

  • NKTR is a no brain buy right now. 20% off its high. Probably 50% off of where its going to be when 102 results are announced in March.

VXX
25.74-0.31(-1.19%)Mar 27 4:00 PMEDT